10-K: Akero Therapeutics Reports Continued Losses Amidst Promising Clinical Trials for MASH Treatment

Akero Therapeutics' 10-K filing reveals ongoing financial losses as the company progresses with clinical trials for Efruxifermin (EFX), a potential treatment for Metabolic dysfunction-associated steatohepatitis (MASH).

Summary

• Akero Therapeutics, a clinical-stage biopharmaceutical company, reported a net loss of $252.1 million for the year ended December 31, 2024, compared to a net loss of $151.8 million in 2023.
• The company is focused on developing Efruxifermin (EFX) for the treatment of MASH and has initiated a Phase 3 clinical program called SYNCHRONY.
• The SYNCHRONY program consists of three trials: Outcomes, Histology, and Real-World, designed to support marketing approval applications.
• Preliminary topline week 96 results from the SYMMETRY Phase 2b trial showed that 39% of patients treated with 50mg EFX experienced reversal of cirrhosis with no worsening of MASH, compared to 15% for placebo.
• Preliminary topline week 96 results from the HARMONY Phase 2b trial showed that 75% of patients treated with 50mg EFX experienced at least a one-stage improvement in liver fibrosis with no worsening of MASH, compared to 24% for placebo.
• The company expects to incur significant expenses for at least the next several years as it advances EFX through later-stage clinical development.
• As of December 31, 2024, Akero had cash, cash equivalents, and marketable securities totaling $797.8 million.
• The company believes that its existing cash, cash equivalents and marketable securities, together with the proceeds from a January 2025 public offering, will be sufficient to fund its current operating plan into 2028.
• Akero has a loan agreement with Hercules Capital, with outstanding borrowings of $35.0 million as of December 31, 2024.
• The company is subject to various risks, including those related to clinical development, manufacturing, competition, intellectual property, and government regulation.

Sentiment

Score: 6

Explanation: The document presents a mixed sentiment. While the company reports significant losses, it also highlights promising clinical trial results and a strong cash position. The overall sentiment is cautiously optimistic.

Positives

• Promising Phase 2b trial results for EFX in treating MASH.
• Initiation of Phase 3 clinical program (SYNCHRONY).
• Strong cash position of $797.8 million as of December 31, 2024.
• Expectation that current financial resources will fund operations into 2028.
• FDA Fast Track and Breakthrough Therapy designations for EFX.

Negatives

• Significant net losses reported for the years ended December 31, 2024, 2023 and 2022.
• No products approved for commercial sale and no revenue generated to date.
• Dependence on the success of EFX, its only product candidate.
• Reliance on third parties for clinical trials and manufacturing.
• Intense competition in the biotechnology industry.

Risks

• Risks related to clinical development, including enrollment and retention of patients in clinical trials.
• Substantial competition from other pharmaceutical and biotechnology companies.
• Potential failures or delays in clinical trials.
• Reliance on third parties for clinical trials and manufacturing.
• Difficulties in manufacturing product candidates.
• Dependence on the success of EFX.
• Requirement to make significant payments under the Amgen license agreement.
• Lengthy and unpredictable regulatory approval processes.
• Potential for harmful side effects after regulatory approval.
• Exposure to anti-kickback, fraud and abuse, and transparency laws.
• Need for additional capital to finance operations.
• Potential limitations on the use of net operating loss carryforwards.
• Volatility in the market price of the company's stock.

Future Outlook

Akero expects to continue to incur significant expenses for at least the next several years as it advances EFX through later-stage clinical development, develops additional product candidates and seeks regulatory approval of any product candidates that complete clinical development. The company believes that its existing cash, cash equivalents and marketable securities, together with the proceeds from a January 2025 public offering, will be sufficient to fund its current operating plan into 2028.

Industry Context

The document provides context on the competitive landscape in the MASH treatment market, noting that several pharmaceutical and biotechnology companies are pursuing the development or marketing of pharmaceuticals that target MASH. It also discusses the FDA approval of the first therapy for treatment of adults with noncirrhotic MASH with moderate to advanced liver fibrosis.

Comparison to Industry Standards

• The document mentions Rezdiffra TM , the first FDA-approved therapy for noncirrhotic MASH, as a competitor.
• The document notes that many MASH therapeutic candidates have had discouraging clinical trial results due to unfavorable efficacy and/or safety results, with a substantial number of programs discontinued.
• The document states that no compound other than EFX has been shown in clinical trials to statistically significantly reverse cirrhosis.

Legal Proceedings

• A purported stockholder of the Company filed a lawsuit, captioned Klobus v. Akero Therapeutics, Inc., No. 3:24-cv-02534 (N.D. Cal.), in the U.S. District Court for the Northern District of California against the Company and three of its officers.
• The suit asserts claims under the Exchange Act for alleged misstatements and omissions regarding the Company's Phase 2b SYMMETRY study.
• The complaint seeks damages in an unspecified amount.
• The Company intends to vigorously defend against the lawsuit.

Stakeholder Impact

• Shareholders: Potential for increased stock value if EFX is successfully developed and commercialized.
• Employees: Job security and potential for career advancement.
• Patients: Access to a potential new treatment for MASH.
• Third-party payors: Potential for cost savings if EFX is more effective than existing treatments.

Next Steps

• Continue clinical development of EFX.
• Pursue regulatory approvals for EFX.
• Explore strategic collaborations.
• Evaluate opportunities to develop EFX for additional indications.
• Enhance position as a leading metabolic disease company by developing, acquiring or in-licensing additional investigational product candidates.

Key Dates